InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,658.00
(
0.32%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
84.17
(
0.26%
)
Bitcoin
62,916.10
(
-0.21%
)
Post# of 62488
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

tradesmart

Send PM Follow Ignore
Followers 0
Posts 6645
Boards Moderated 1
Alias Born 12/08/2015

tradesmart

Re: None

Wednesday, 01/13/2016 2:28:17 PM

Wednesday, January 13, 2016 2:28:17 PM

Post# of 62488
$IMNP's lead product candidate, Bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid. Other indications considered for Bertilimumab development include atopic dermatitis, Crohn's disease, severe asthma and inflammatory liver diseases (NASH).

Learn More: http://www.immunepharma.com/product-portfolio/bertilimumab-draft/
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up